Maat Pharma Phase III microbiome trial hits endpoints as stock soar
French clinical-stage biotechnology and microbiome therapy company MaaT Pharma has seen success with its Phase III trial of MaaT013 meeting its primary endpoints, leading to a jump in the company’s ...
Market Fears of Potential Selling Pressure From Possible Silk Road Sale is Overblown: Van Straten
For the outside world, bitcoin (BTC) dropping $10,000 to $92,000, in a matter of days could signal the end of the bull run. A caveat to this could be that bitcoin continues to consolidate below a ke...
The market hasn’t been this concentrated in at least 60 years. But is it a problem?
The top five companies in the S&P 500 account for a greater chunk of the index than at any time over the last 60 years. Apple Inc. AAPL, Nvidia Corp. NVDA, Microsoft Corp. MSFT, A...
